What matters most? Acuity or Duration? What if Opthea was wrong?, page-2

1. I don't know you, so it's premature for you to consider me your "friend".
2. Its doesn't so much look as though you are asking a question but more as though as you are trying to push a view and sow doubt about the company, presumably for your own purposes.
3. The answer is both acuity and duration are important
4. The company doesn't usually mention competitors and therefore hasn't commented or led investors to believe the market is more or less crowded or otherwise
5. While companies recommend their products are used monthly, most opthalmologists tend to use their own dosing regimes, often prn. You can easily refer to journals to see the common practices
6. The duration of OPT302 in combination with VEGF-A inhibitors hasn't been formally tested. It may not need to be administered monthly